Relapsed or Refractory Large B-cell Lymphoma clinical trials

Metabolically armed CAR-T cells for relapsed B-cell lymphoma

This trial tests a new type of CAR-T cell therapy (Meta10-19) for people with aggressive B-cell lymphoma that has not responded to two or more standard treatments. The therapy is designed to be more powerful inside the body to attack cancer cells.

AlloNK and rituximab for relapsing rheumatologic diseases

This trial tests a new natural killer (NK) cell therapy called AlloNK given with rituximab for people with certain autoimmune diseases (rheumatoid arthritis, Sjögren's disease, inflammatory myopathies, or systemic sclerosis) that have not responded well to standard treatments. The goal is to see if this combination can better control the disease.

CAR-T therapy for relapsed or refractory IgG4-related disease

This trial tests whether a special type of immune cell therapy (CAR-T) can help people whose IgG4-related disease persists despite steroids or rituximab. It focuses on those with inflammation in two or more major organs.

Durvalumab plus lenalidomide for relapsed T-cell lymphoma

This study tests a combination of two drugs—durvalumab (an immunotherapy) and lenalidomide (a targeted therapy)—to see if they are safe and effective for people with T-cell lymphoma that has come back or not responded to treatment. It aims to harness your immune system to fight the cancer while also attacking the cancer cells directly.

Testing trametinib and steroid plus chemo for relapsed blood cancers

This early-phase trial tests whether adding trametinib and dexamethasone to standard chemotherapy can improve outcomes for children whose blood cancer has come back or did not respond. Because it is a Phase 1/2 study, the main goal is to see safety and learn the best way to treat your specific cancer type.

Targeted triple-combination treatment for children with relapsed blood cancers

This Phase 1/2 study tests a multi-drug combination (ruxolitinib, venetoclax, dexamethasone, plus chemotherapy) for children whose blood cancer has come back or did not respond. It aims to reduce the cancer by targeting specific genetic changes and may offer a new option when standard treatments have not worked.

CAR T-cell therapy for CD19-positive leukemias and lymphomas

This trial tests a new immune therapy that uses your own cells (CAR T-cells) to find and attack cancer cells with the CD19 protein. It is for people with certain types of leukemia or lymphoma that have not responded to other treatments.

Study of zanubrutinib and tislelizumab for lymphoma after CAR-T

This trial tests two new drugs (zanubrutinib and tislelizumab) for people with large B-cell lymphoma that has come back or not responded after CAR-T therapy. The goal is to see if these drugs can help when CAR-T hasn't worked.

Relma-cel and Tislelizumab for CNS Lymphoma

This trial tests a combination of two drugs for people with large B-cell lymphoma that has spread to the brain or spinal cord and has come back or not responded well to earlier treatments. The first drug, Relma-cel, is a type of immunotherapy that helps your immune system attack cancer cells. The second drug, Tislelizumab, helps keep your immune system active against the cancer.

UTAA09 injection for relapsed or refractory blood cancers

This trial tests an investigational cell therapy called UTAA09 for people with CD19-positive B-cell blood cancers that have come back or not responded to treatment. It aims to see if this treatment is safe and effective.

CAR T-cell treatment versus standard care for relapsed lymphoma

This trial tests a CAR T-cell therapy (MB-CART2019.1) against standard treatment in people with certain types of aggressive B-cell lymphoma that has come back or didn’t respond to the first treatment. It aims to improve how well the lymphoma responds and to check for side effects and safety.

Testing a new CAR-T therapy for relapsed myeloma

This Phase 1/2 study tests C-CAR088, a lab-made immune therapy, in people with multiple myeloma that has come back or did not respond. It is for patients who have already had several standard treatments and whose disease is still measurable.

Inaticabtagene Autoleucel for Relapsed or Refractory ALL

This trial tests a personalized cell therapy for adults with B-cell acute lymphoblastic leukemia (ALL) that has come back or hasn't responded to treatment. It may offer a new option for people who need additional treatment.

UTAA09 cell therapy for lymphoma

This trial tests a new cell therapy called UTAA09 for people with certain types of lymphoma that have not been treated with CAR T-cells before. It aims to see if the treatment is safe and works against tumors that have CD19 or CD20 proteins.

Natural killer cells plus mogamulizumab for skin lymphoma

This early-phase study tests a combination of “natural killer” immune cells and a medicine called mogamulizumab to treat certain skin lymphomas that have come back or did not respond. It may help your immune system better find and attack cancer cells.

Testing a CD19 CAR T cell treatment for relapsed blood cancers

This Phase 1 study tests the safety and best dose of a CD19 CAR T cell therapy (azer-cel) in people whose B-cell blood cancer has returned or did not respond to treatment. It may help people with relapsed/refractory B-ALL or certain aggressive or large B-cell lymphomas, including after or before prior CAR T treatment.

Testing mini-CHOP versus adding polatuzumab for lymphoma

This study compares two lymphoma treatments: mini-CHOP alone versus mini-CHOP plus a drug called polatuzumab vedotin. It aims to see which regimen works better and is tolerable for older or frail people with certain types of aggressive B-cell lymphoma.

Pembrolizumab and olaparib for relapsed peripheral T-cell lymphoma

This trial tests whether combining two targeted drugs, pembrolizumab and olaparib, can help people with peripheral T-cell lymphoma that has come back or not responded to previous treatment. The goal is to find a new option for this type of cancer.

CAR-T therapy after stem cell transplant for high-risk B-cell lymphoma

This trial tests a combination treatment: a stem cell transplant followed by CAR-T cell therapy for people with B-cell lymphoma that has come back or not responded to treatment. It is for those with high-risk features like large tumors or certain genetic changes.

Testing a new immune cell therapy for relapsed B-cell lymphoma

This trial is testing a new treatment called CD19x22 CAR T cells for people with certain types of B-cell lymphoma that have come back or not responded to other treatments. The therapy uses your own immune cells, which are modified in a lab to better attack the cancer.

Testing GT801 cell therapy for blood cancer and AIHA

This study tests an investigational cell therapy called GT801 for people whose CD19-positive blood cancer (B-ALL, CLL, or B-NHL) or autoimmune hemolytic anemia (AIHA) has not responded to standard treatments. The therapy is made from your own immune cells, modified to target and destroy cancer cells or abnormal immune cells.

IBR900 cell therapy for relapsed/refractory B-cell lymphoma

This trial tests a new cell therapy (IBR900) for people with a type of B-cell lymphoma that has come back or not responded to prior treatments. The therapy uses your own immune cells to target and kill the cancer cells.

Study of four medicines for children with difficult blood cancers

This Phase 1/2 trial tests a combination of medicines (dasatinib, venetoclax, dexamethasone, cyclophosphamide, and cytarabine) in children and teens whose blood cancer has come back or did not respond to treatment. It aims to see whether this approach can control the cancer while checking what doses are safe.

In Vivo CD19/CD20 CAR T-Cell Therapy for Relapsed/Refractory B-Cell Lymphoma